GO:1900131 negative regulation of lipid binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900131 (negative regulation of lipid binding) is a biological process that stops, prevents, or reduces the frequency, rate, or extent of lipid binding.
• It is distinct from general lipid metabolism; it specifically controls the availability of lipids for binding by proteins, thereby influencing signaling and membrane dynamics.
• Key molecular players include lipid-binding proteins such as RARRES2, HS1BP3, and CD1 family members, which are subject to negative regulation.
• Dysregulation of this process is implicated in cancer progression, acute lung injury, and immune disorders.
• Experimental models for studying GO:1900131 include CRISPR knockout, point mutation, and overexpression of genes encoding lipid-binding proteins or their regulators.
• Understanding negative regulation of lipid binding can reveal therapeutic targets for metabolic and inflammatory diseases.
Description
The Gene Ontology (GO) term GO:1900131, negative regulation of lipid binding, describes any process that stops, prevents, or reduces the frequency, rate, or extent of lipid binding. Lipid binding is a fundamental molecular function in which proteins or other molecules interact with lipids such as fatty acids, phospholipids, or sterols. This interaction is critical for membrane structure, signal transduction, and energy homeostasis. Negative regulation of lipid binding ensures that lipid-protein interactions are tightly controlled, preventing aberrant signaling or metabolic imbalances. Researchers study this process to understand how cells modulate lipid availability and how disruptions contribute to diseases like cancer and inflammation. The term is part of the biological process ontology and is supported by experimental evidence from studies on autophagy, immune regulation, and lipid metabolic reprogramming.
negative regulation of lipid binding At A Glance
| GO ID | GO:1900131 |
|---|---|
| GO term | negative regulation of lipid binding |
| Ontology | biological_process |
| Synonym | down regulation of lipid binding, down-regulation of lipid binding, downregulation of lipid binding, inhibition of lipid binding |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of lipid binding |
| Related processes | Autophagy regulation, immune cell lipid presentation, lipid metabolic reprogramming |
| Evidence | Experimental evidence from studies on HS1BP3, CD1, and RARRES2 |
What Is GO:1900131?
Negative regulation of lipid binding (GO:1900131) refers to any biological process that decreases the frequency, rate, or extent of lipid binding. In other words, it encompasses mechanisms that inhibit or reduce the interaction between lipids and their binding partners, such as proteins or other biomolecules. This regulation can occur through changes in lipid availability, modification of binding sites, or sequestration of lipids away from their targets.
Why Is negative regulation of lipid binding Important in Cell Biology?
Negative regulation of lipid binding is crucial for maintaining cellular homeostasis because uncontrolled lipid binding can lead to aberrant signaling, membrane destabilization, and metabolic disorders. For instance, in autophagy, the protein HS1BP3 negatively regulates lipid binding to control autophagosome formation. In immune responses, CD1 molecules present lipids to T cells, and their negative regulators prevent excessive immune activation. In cancer, RARRES2 modulates lipid metabolic reprogramming to influence brain metastasis in triple-negative breast cancer. Thus, understanding this process provides insights into fundamental cell biology and potential therapeutic targets.
• Controls autophagy by regulating lipid binding to autophagosomal membranes.
• Modulates immune responses by limiting lipid presentation by CD1 molecules.
• Influences cancer progression through lipid metabolic reprogramming.
• Protects against acute lung injury by inhibiting ferroptosis via lipid binding regulation.
• Regulates ion channels such as TRP channels through voltage-lipid connections.
• Impacts cholesterol synthesis via glutamine sensing.
• Affects lipid synthesis in mammary epithelial cells through SREBP-1.
• Plays a role in calcium-sensing receptor allosteric modulation.
• Potential target for therapies in metabolic and inflammatory diseases.
What Happens During negative regulation of lipid binding?
Initiation of negative regulation
In simple terms: The cell senses that lipid binding needs to be reduced and triggers a response.
Negative regulation of lipid binding can be initiated by various cellular cues, such as changes in lipid availability, stress signals, or immune activation. For example, in autophagy, the protein HS1BP3 is recruited to membranes where it acts as a negative regulator of lipid binding, preventing excessive autophagosome formation. Similarly, in immune cells, CD1 molecules present lipids, and their negative regulators are induced to avoid overstimulation.
Mechanisms of reducing lipid binding
In simple terms: The cell uses different strategies to stop lipids from binding to proteins.
Mechanisms include sequestration of lipids by other molecules, post-translational modifications of lipid-binding proteins that reduce their affinity, or degradation of the lipid-binding proteins. For instance, RARRES2 regulates lipid metabolic reprogramming, which can alter the availability of lipids for binding. Additionally, STAT6 inhibits ferroptosis by regulating the P53/SLC7A11 pathway, which may affect lipid binding indirectly.
Downstream effects on cellular processes
In simple terms: Reducing lipid binding changes what the cell does next.
The reduction in lipid binding can lead to decreased signaling through lipid-dependent pathways, altered membrane composition, and changes in autophagy or immune responses. For example, negative regulation of lipid binding by HS1BP3 inhibits autophagy, while in cancer, modulation of lipid binding can affect metastatic potential.
Feedback and termination
In simple terms: The cell monitors the process and can reverse it when needed.
Negative regulation of lipid binding is subject to feedback loops. For instance, glutamine sensing licenses cholesterol synthesis, which may in turn affect lipid binding. The process can be terminated when lipid binding needs to be restored, often through degradation or inactivation of the negative regulators.
Key Genes Involved in GO:1900131 negative regulation of lipid binding
The following genes and proteins are involved in negative regulation of lipid binding, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RARRES2 | Regulates lipid metabolic reprogramming | Implicated in brain metastasis of triple-negative breast cancer |
| HS1BP3 | Negative regulator of autophagy through membrane lipids | Provides a novel mechanism of negative autophagy regulation |
| CD1 | Presents lipids to T cells; subject to negative regulation | Immune regulation and lipid antigen presentation |
| STAT6 | Inhibits ferroptosis via P53/SLC7A11 pathway | Protects against acute lung injury |
| SLC7A11 | Cystine/glutamate antiporter; affects lipid peroxidation | Regulated by STAT6 in ferroptosis |
| P53 | Tumor suppressor; regulates ferroptosis | Involved in STAT6-mediated protection |
| CaSR | Calcium-sensing receptor; modulated by lipids | Allosteric modulation and G-protein selectivity |
| TRP channels | Ion channels regulated by voltage-lipid connection | Regulation by lipids |
| SREBP-1 | Transcription factor regulating lipid synthesis | Transcriptional regulation of lipid synthesis |
| Glutamine | Metabolite that licenses cholesterol synthesis | Links glutamine sensing to lipid metabolism |
| Lipid-binding proteins | Various proteins that bind lipids | General role in lipid binding regulation |
| Autophagy-related proteins | Proteins involved in autophagosome formation | Regulated by HS1BP3 |
| Immune receptors | Receptors that recognize lipids | CD1 family |
| Metabolic enzymes | Enzymes in lipid metabolism | Affect lipid availability |
| Membrane lipids | Structural components of membranes | Targets of negative regulation |
| Cholesterol | Sterol lipid | Synthesis regulated by glutamine sensing |
| Fatty acids | Lipid molecules | Binding regulated in various contexts |
How Is negative regulation of lipid binding Regulated?
Negative regulation of lipid binding is itself regulated by various signaling pathways. For example, glutamine sensing can license cholesterol synthesis, which may impact lipid binding. The STAT6 pathway inhibits ferroptosis by regulating P53/SLC7A11, indirectly affecting lipid binding. Additionally, transcriptional regulation by SREBP-1 controls lipid synthesis, which can influence the availability of lipids for binding. These regulatory mechanisms ensure that lipid binding is tightly controlled in response to cellular needs.
negative regulation of lipid binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RARRES2 | Triple-negative breast cancer brain metastasis | Knockout or overexpression in breast cancer cell lines |
| STAT6 | Acute lung injury | Knockout mice or cell models |
| CD1 | Immune disorders | Knockout mice or human immune cells |
| HS1BP3 | Autophagy-related diseases | Knockout or point mutation in cell lines |
| SREBP-1 | Metabolic disorders | Overexpression or knockout in mammary epithelial cells |
Cancer
Dysregulation of negative regulation of lipid binding is implicated in cancer. RARRES2 regulates lipid metabolic reprogramming to mediate brain metastasis in triple-negative breast cancer. This suggests that targeting lipid binding pathways could be a therapeutic strategy.
Acute Lung Injury
STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating the P53/SLC7A11 pathway. This pathway involves lipid peroxidation, a process related to lipid binding, indicating a protective role for negative regulation of lipid binding.
Immune Disorders
CD1 molecules present lipids to T cells, and their negative regulators prevent excessive immune activation. Defects in this regulation can lead to autoimmune or inflammatory conditions.
From negative regulation of lipid binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate lipid binding? | CRISPR knockout of gene X followed by lipid binding assays |
| What is the effect of a point mutation in a lipid-binding protein? | CRISPR point mutation knock-in |
| How does overexpression of a regulator affect lipid binding? | CRISPR overexpression (e.g., CRISPRa) |
| Where does the protein localize during negative regulation? | Tagged knock-in with fluorescent protein |
| What are the downstream targets of negative regulation? | CRISPR library screening |
| Can we identify small molecules that modulate this process? | High-throughput screening with CRISPR knockout libraries |
How to Study the negative regulation of lipid binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipid overlay assay | Direct binding of proteins to immobilized lipids | Identify lipid-binding proteins and regulators |
| Surface plasmon resonance | Real-time binding kinetics | Quantify affinity and kinetics of lipid-protein interactions |
| CRISPR knockout screen | Gene function in lipid binding | Identify negative regulators of lipid binding |
| CRISPR activation screen | Gene overexpression effects | Identify enhancers of negative regulation |
| Proteomics | Protein abundance and modifications | Discover changes in lipid-binding proteins |
| Lipidomics | Lipid composition and abundance | Assess lipid availability |
| Fluorescence microscopy | Localization and dynamics of lipid binding | Visualize negative regulation in cells |
Lipid Binding Assays
Lipid binding can be measured using techniques such as lipid overlay assays, surface plasmon resonance, or fluorescence polarization. These methods quantify the interaction between lipids and proteins and can be used to assess the effect of negative regulators.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate lipid binding. For example, a screen could use a lipid-binding reporter to sort cells with altered lipid binding.
Proteomics and Lipidomics
Mass spectrometry-based proteomics and lipidomics can reveal changes in protein-lipid interactions and lipid composition upon modulation of negative regulators.
Imaging
Fluorescence microscopy with lipid probes or tagged proteins can visualize lipid binding in live cells and tissues, providing spatial and temporal information.
How CRISPR Can Be Used to Study GO:1900131 negative regulation of lipid binding
Knockout
CRISPR knockout of candidate genes can determine whether they are required for negative regulation of lipid binding. For example, knocking out HS1BP3 would test its role in autophagy-related lipid binding.
Point Mutation
Introducing point mutations in lipid-binding domains or regulatory sites can dissect the precise residues involved in negative regulation. This is useful for genes like RARRES2.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP) allows visualization and pull-down of lipid-binding complexes. This can be applied to CD1 or HS1BP3.
Overexpression
Overexpression of negative regulators can suppress lipid binding and reveal downstream effects. For instance, overexpressing STAT6 may inhibit ferroptosis via lipid binding regulation.
How EDITGENE Supports negative regulation of lipid binding Research
Researchers studying negative regulation of lipid binding-related genes often need to determine whether a candidate gene is causally involved in the process or is merely correlated. EDITGENE provides comprehensive CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid binding research.
Frequently Asked Questions About negative regulation of lipid binding
What is GO:1900131?
GO:1900131 is the Gene Ontology term for negative regulation of lipid binding, a biological process that reduces the frequency, rate, or extent of lipid binding.
What genes are involved in negative regulation of lipid binding?
Genes such as RARRES2, HS1BP3, CD1, STAT6, and SREBP-1 have been implicated in negative regulation of lipid binding.
How is negative regulation of lipid binding studied?
It is studied using lipid binding assays, CRISPR screens, proteomics, and imaging techniques.
Why is negative regulation of lipid binding important?
It maintains cellular homeostasis and prevents diseases like cancer and acute lung injury.
What diseases are associated with dysregulation of lipid binding?
Cancer, acute lung injury, and immune disorders are associated with dysregulation of lipid binding.
What are the synonyms for GO:1900131?
Synonyms include down regulation of lipid binding, down-regulation of lipid binding, downregulation of lipid binding, and inhibition of lipid binding.
Which ontology does GO:1900131 belong to?
It belongs to the biological_process ontology.
What is the definition of negative regulation of lipid binding?
Any process that stops, prevents or reduces the frequency, rate or extent of lipid binding.
How can CRISPR be used to study negative regulation of lipid binding?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to manipulate genes and study their effects on lipid binding.
What services does EDITGENE offer for studying this process?
EDITGENE offers knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Negative regulation of lipid binding (GO:1900131) is a critical biological process that controls lipid-protein interactions to maintain cellular homeostasis. Its dysregulation is linked to cancer, acute lung injury, and immune disorders. By leveraging CRISPR technologies and advanced research methods, scientists can uncover the molecular mechanisms and identify therapeutic targets. EDITGENE provides comprehensive tools to accelerate this research.
References
- 1. Li YQ et al.. 2023. RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer.. Mil Med Res 10(1):34 PMID: 37491281
- 2. Garcia BM et al.. 2024. Glutamine sensing licenses cholesterol synthesis.. EMBO J 43(23):5837-5856 PMID: 39433901
- 3. Yang Y et al.. 2022. STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway.. Cell Death Dis 13(6):530 PMID: 35668064
- 4. Yin Z et al.. 2017. HS1BP3 provides a novel mechanism of negative autophagy regulation through membrane lipids.. Autophagy 13(5):779-780 PMID: 28323521
- 5. He F et al.. 2024. Allosteric modulation and G-protein selectivity of the Ca(2+)-sensing receptor.. Nature 626(8001):1141-1148 PMID: 38326620
- 6. Nilius B et al.. 2007. Regulation of TRP channels: a voltage-lipid connection.. Biochem Soc Trans 35(Pt 1):105-8 PMID: 17233613
- 7. Shahine A et al.. 2023. CD1 displays its own negative regulators.. Curr Opin Immunol 83:102339 PMID: 37245411
- 8. Ma L et al.. 2012. Transcriptional regulation of lipid synthesis in bovine mammary epithelial cells by sterol regulatory element binding protein-1.. J Dairy Sci 95(7):3743-55 PMID: 22720931
